SEARCH

SEARCH BY CITATION

References

  • 1
    Balch, C. M., J. E. Gershenwald, S. J. Soong, J. F. Thompson, M. B. Atkins, D. R. Byrd, et al. 2009. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27:61996206.
  • 2
    Davies, H., G. R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, et al. 2002. Mutations of the BRAF gene in human cancer. Nature 27:949954.
  • 3
    Meier, F., B. Schittek, S. Busch, C. Garbe, K. Smalley, K. Satyamoorthy, et al. 2005. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci. 10:29863001.
  • 4
    Chapman, P. B., A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:25072516.
  • 5
    Sosman, J. A., K. B. Kim, L. Schuchter, R. Gonzalez, A. C. Pavlick, J. S. Weber, et al. 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366:707714.
  • 6
    Staudt, M., K. Lasithiotakis, U. Leiter, F. Meier, T. Eigentler, M. Bamberg, et al. 2010. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br. J. Cancer 102:12131218.
  • 7
    Elaimy, A. L., A. R. Mackay, W. T. Lamoreaux, R. K. Fairbanks, J. J. Demakas, B. S. Cooke, et al. 2011. Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients. World J. Surg. Oncol. 9:69.
  • 8
    Chiarion-Sileni, V., M. Guida, L. Ridolfi, A. Romanini, P. Del Bianco, J. Pigozzo, et al. 2011. Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine-based regimens. Br. J. Cancer 104:18161821.
  • 9
    Margolin, K., M. S. Ernstoff, O. Hamid, D. Lawrence, D. McDermott, I. Puzanov, et al. 2012. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13:459465.
  • 10
    Dummer, R., J. Rinderknecht, S. M. Goldinger, I. Wagner, L. Mitchell, M. L. Veronese et al. 2011. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J. Clin. Oncol. 29(suppl.): abstr 8548.
  • 11
    Kirkwood, J. M., G. V. Long, U. Trefzer, M. A. Davies, P. A. Ascierto, P. B. Chapman, et al. 2012. BREAK-MB: a phase II study assessing overall intracranial response rate to dabrafenib (GSK2118436) in patients with BRAFV600E/K mutation-postive melanoma with brain metastases. J. Clin. Oncol. 30(suppl.): abstr 8501.
  • 12
    Lasithiotakis, K., T. Sinnberg, B. Schittek, K. T. Flaherty, D. Kulms, E. Maczey, et al. 2008. Combined inhibition of MAPK and mTOR signalling pathways potently inhibits growth, induces apoptosis and abrogates invasive tumour growth of melanoma cells. J. Invest. Dermatol. 128:20132023.
  • 13
    Mancianti, M. L., M. Herlyn, D. Weil, J. Jambrosic, U. Rodeck, D. Becker, et al. 1988. Growth and phenotypic characteristics of human nevus cells in culture. J. Invest. Dermatol. 90:134141.
  • 14
    Meier, F., M. Nesbit, M. Y. Hsu, B. Martin, P. Van Belle, D. E. Elder, et al. 2000. Human melanoma progression in skin reconstructs: biological significance of bFGF. Am. J. Pathol. 156:193200.
  • 15
    Sinnberg, T., K. Lasithiotakis, H. Niessner, B. Schittek, K. T. Flaherty, D. Kulms, et al. 2009. Inhibition of PI3K-AKT-mTOR signalling sensitises melanoma cells to cisplatin and temozolomide. J. Invest. Dermatol. 129:15001515.
  • 16
    Mittapalli, R. K., S. Vaidhyanathan, R. Sane, W. F. Elmquist. 2012. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J. Pharmacol. Exp. Ther. 342:3340.
  • 17
    Durmus, S., R. W. Sparidans, E. Wagenaar, J. H. Beijnen, and A. H. Schinkel. 2012. Oral availability and brain penetration of the B-RAF(V600E) inhibitor vemurafenib can be enhanced by the p-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol. Pharm. 9:32363245.
  • 18
    Fidler, I. J. 2011. The role of the organ microenvironment in brain metastasis. Semin. Cancer Biol. 21:107112.
  • 19
    Gerstner, E., and R. L. Fine. 2007. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J. Clin. Oncol. 25:23062312.
  • 20
    Amaravadi, R., K. Kim, K. Flaherty, P. Chapman, I. Puzanov, J. Sosman, et al. 2011. Prolonged response to vemurafenib in patients with BRAFV600E-mutant melanoma with low tumor burden at baseline. Pigment Cell Melanoma Res. 24:1024; abstr. SMR-P3.
  • 21
    Davies, M. A., K. Stemke-Hale, E. Lin, C. Tellez, W. Deng, Y. N. Gopal, et al. 2009. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin. Cancer Res. 15:75387546.
  • 22
    Madhunapantula, S. V., and G. P. Robertson. 2009. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 22:400419.
  • 23
    Stahl, J. M., A. Sharma, M. Cheung, M. Zimmerman, J. Q. Cheng, M. W. Bosenberg, et al. 2004. Deregulated AKT3 activity promotes development of malignant melanoma. Cancer Res. 64:70027010.
  • 24
    Lorger, M. 2012. Tumor microenvironment in the brain. Cancers 4:218243.
  • 25
    Park, E. S., S. J. Kim, S. W. Kim, S. L. Yoon, S. H. Leem, S. B. Kim, et al. 2011. Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastases. Proc. Natl. Acad. Sci. USA 108:1745617461.
  • 26
    Seike, T., K. Fujita, Y. Yamakawa, M. A. Kido, S. Takiguchi, N. Teramoto, et al. 2010. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin. Exp. Metastasis 28:1325.
  • 27
    Sierra, A., J. E. Price, M. Garcia-Ramirez, O. Méndez, L. López, and A. Fabra. 1997. Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. Lab. Invest. 77:357368.